middle.news
Paradigm Advances Phase 3 Osteoarthritis Trial, Eyes $112M Capital Raise
1:51pm on Tuesday 29th of April, 2025 AEST
•
Healthcare
Read Story
Paradigm Advances Phase 3 Osteoarthritis Trial, Eyes $112M Capital Raise
1:51pm on Tuesday 29th of April, 2025 AEST
Key Points
Centralised ethics approval obtained in Australia for phase 3 trial
Advanced Clinical appointed as global CRO for trial execution
$6.3 million received from FY24 R&D Tax Incentive refund
Cash balance stands at $24.56 million as of March 31, 2025
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Paradigm Biopharmaceuticals (ASX:PAR)
OPEN ARTICLE